Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thioureidoiminomethylpyridinium perchlorate
- Development stage
- Unknown
- Lead developer
- Pharmasyntez
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Perchlozon (thioureidoiminomethylpyridinium perchlorate) is an oral small molecule anti-tuberculosis drug developed by Pharmasyntez in collaboration with the A.E. Favorsky Irkutsk Institute of Chemistry and the Saint-Petersburg Research Institute of Phthisiopulmonology. Approved in the Russian Federation in 2012, Perchlozon is indicated for the treatment of pulmonary tuberculosis, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. Chemically classified as a thiosemicarbazone, Perchlozon acts as a prodrug that requires bioactivation by the mycobacterial FAD-containing monooxygenase EthA. Once activated, it targets and inhibits the FAS-II dehydratase complex HadABC (comprising HadA, HadB, and HadC subunits), thereby disrupting mycolic acid biosynthesis and compromising the integrity of the mycobacterial cell wall.
- Brand names
- PerchlozonPerchlozone
- Other names
- 4-thioureidoiminomethylpyridinium perchlorateтиоуреидоиминометилпиридиния перхлорат
02
Targets
HadAB/HadBC ((3R)-hydroxyacyl-ACP dehydratase HadAB complex)
Beyond the preview
Go deeper on thioureidoiminomethylpyridinium perchlorate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thioureidoiminomethylpyridinium perchlorate.